ARCT has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on ...

The firm increased its portfolio allocation in ARCT by 38.78% over the last quarter. FKASX - Federated Kaufmann Small Cap Fund Shares holds 2,198K shares representing 8.11% ownership of the company.

Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of directors since June 2024. Published first on TheFly ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $63.00. Ed Arce has given his Buy ...

The company's pipeline includes ARCT-810, a treatment for ornithine transcarbamylase deficiency in Phase 2 trials, ARCT-154, a COVID-19 vaccine candidate in Phase 3 trials in Vietnam, and ARCT-032 ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last ... standing at 0.11. Within the domain of banking ...

I was privileged to byline the cover story of the last print issue of PC Magazine, the Windows 7 review, and I’ve witnessed every Microsoft win and misstep up to the latest Windows 11.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...